Enzon NDA: Firm's first NDA filing is for PEG-adenosine deaminase (PEG-ADA), for treatment of severe combined immunodeficiency disease in children. "PEG-ADA is the first of four Enzon products currently in clinical development for which NDA's are expected to be filed in the next one to three years," company said.
You may also be interested in...
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.